2004
Cannabinoid ‘model’ psychosis, dopamine–cannabinoid interactions and implications for schizophrenia
D'souza D, Cho H, Perry E, Krystal J. Cannabinoid ‘model’ psychosis, dopamine–cannabinoid interactions and implications for schizophrenia. 2004, 142-165. DOI: 10.1017/cbo9780511543630.012.Peer-Reviewed Original ResearchReceptor dysfunctionCannabinoid compoundsCannabis consumptionPathophysiology of psychosisPathophysiology of schizophreniaRecent pharmacological studiesPrincipal psychoactive constituentEffects of exposurePostmortem studiesNormal controlsPsychotic symptomsPsychotic disordersPharmacological studiesPsychosisPsychoactive constituentPathophysiologyΔ9-tetrahydrocannabinolSchizophreniaCannabisDysfunctionAssociationPossible mechanismPatientsSymptomsPharmacological
2001
Lower prolactin bioactivity in unmedicated schizophrenic patients
Warner M, Walker A, D'Souza D, Lee D, Nasseri D, Peabody C. Lower prolactin bioactivity in unmedicated schizophrenic patients. Psychiatry Research 2001, 102: 249-254. PMID: 11440775, DOI: 10.1016/s0165-1781(01)00256-6.Peer-Reviewed Original ResearchConceptsSchizophrenic patientsControl subjectsMale control subjectsUnmedicated schizophrenic patientsTuberoinfundibular dopamine systemProlactin abnormalitiesMale patientsNeuroleptic medicationProlactin bioactivityLong-term effectsPRL valuesNormal controlsDopamine systemPRL ratioPatientsSchizophrenic groupDifferent molecular formsRIABA techniqueSubjectsMolecular formsEarlier findingsMedications